1st Annual European Symposium on Lung Cancers™
1st Annual European Symposium on Lung Cancers™

7-8 July 2017
Barcelona, Spain

Crowne Plaza Barcelona – Fira Center
Av. de Rius i Taulet, 1,
08004 Barcelona, Spain
Tel: +34 934 26 22 23

Hotel Information Link

The field of lung cancer therapy now encompasses several cutting-edge approaches, including personalized medicine, targeted agents, and immunotherapy. After decades of therapeutic nihilism, the treatment of patients with lung cancer has rapidly moved to the vanguard of clinical oncology, incorporating treatments with a superior therapeutic index compared to the previous standard of cytotoxic regimens. These practice-changing discoveries have the potential to improve patient outcomes, but also place an increased demand on physicians to understand new paradigms in molecular testing, treatment selection, and managing adverse events with new categories of therapies.

We are pleased to announce the 1st Annual European Symposium on Lung Cancers™, which will focus on these “Disruptive Therapeutic Innovations in Lung Cancer” and how clinicians can best incorporate these new approaches. This highly interactive and practical program will include internationally recognized experts in lung cancer describing recent key studies in lung cancer, as well as extensive case-based discussions that go beyond the data in addressing challenges faced in the clinic. This meeting will also allow for participants to engage directly with the experts and with their peers to share their perspectives, personal experiences, and approaches to optimize care for their patients with lung cancer.

2017 Featured Topics

  • Immunotherapy as a new standard of care in the first-line setting and in previously treated patients
  • Current and future approaches for selecting patients for immunotherapy
  • Management of immune-related adverse events
  • New therapies for patients with EGFR mutation-positive and ALK-rearranged NSCLC
  • Clinical data on targeted agents for other oncogenic drivers, including BRAF, MET, and RET
  • The emergence of liquid biopsies for molecular testing, and what oncologists need to know for their optimal application

Program Co-Chairs

Prof. Dr. med. Martin Reck
Head of the Thoracic Oncology and Clinical Trial Departments
Lung Clinic Grosshansdorf
Grosshansdorf, Germany

Jean-Charles Soria, MD, PhD
Cancer Specialist
Chair, Drug Development Department,
Gustave Roussy
Professor of Medicine and Medical Oncology at South-Paris University
Paris, France

European Planning Committee

Enriqueta Felip, MD, PhD
Director Thoracic and Head and Neck Program
Department of Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain

Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE
Honorary Chair in Pulmonary Pathology
Aberdeen University Medical School
Aberdeen, Scotland

Tony Mok, MD
Professor, Dept. of Clinical Oncology
Chinese University of Hong Kong
Hong Kong, China

Solange Peters, MD-PhD, PD-MER
Head Medical Oncology
Chair Thoracic Malignancies
Oncology Department
Lausanne University Hospital
Lausanne, Switzerland

Calendar of Events
Filter By